Colorectal Cancer Treatment Market Analysis

The market is segmented on the basis of treatment type into surgery, chemotherapy, immunotherapy, radiotherapy, targeted therapy, ablation and others, out of which, the targeted therapy segment is anticipated to grab the largest share by the end of 2021 on account of technological advancements and better efficiency of targeted therapy than other therapies, for the treatment of colorectal cancer. Moreover, there is a large availability of prominent targeted therapies, which is also projected to contribute to the growth of the segment during the forecast period.

On the basis of end-user, the general medical & surgical hospitals segment in the global colorectal cancer treatment market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that general medical & surgical hospitals possess well-developed healthcare infrastructure for the diagnosis and treatment of colorectal cancer.

Our in-depth analysis of the global market includes the following segments:

By Treatment Type	Surgery Chemotherapy Immunotherapy Radiotherapy Targeted Therapy Ablation Others
By End-User	General Medical & Surgical Hospitals Specialty Hospitals Clinics Others

Frequently Asked Questions (FAQ)

The rising prevalence of colorectal cancer globally and growth in efficient treatment options are the key factors driving market growth.

The market is anticipated to attain a moderate CAGR over the forecast period, i.e., 2021-2029.

Expensive colorectal cancer treatment therapies and lack of awareness about the disease in lower economic regions are estimated to hamper market growth.

The major players dominating the colorectal cancer treatment market are Genentech, Inc., Eli Lilly and Company, F. Hoffman-La Roche AG, and Bristol Myers Squibb among others.

Colorectal Cancer Treatment Market Analysis